ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas

ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas Jerome Fayette, Isabelle Ray Coquard, Laurent Alberti, Dominique Ranchere, Helen Boyle, Jean-Yves Blay Oncologist 2005; 10: 827-832 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in sarcomas and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the original mechanism of action of ET-743. Explain the management of patients treated with ET-743, including what biological exams are needed because of toxicity and what is the optimal schedule of administration. Choose the best histological subtype of sarcoma for treatment with ET-743 and describe the clinical aim of treatment. Discuss putative combinations of ET-743 with other therapies. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Nov. 28, 2005 Most Recent Review: Nov. 28, 2005* Most Recent Update: Nov. 28, 2005 Date Credit Expires: Nov. 28, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.